Roszdravnadzor (Russia)

Roszdravnadzor (Федеральная служба по надзору в сфере здравоохранения, Federal Service for Surveillance in Healthcare, abbreviated RZN or Росздравнадзор) is the federal executive authority of the Russian Federation responsible for control + supervision of healthcare services, medicines, medical devices + biomedical cell products. It was established 30 June 2004 by Presidential Decree No. 314 + Government Decree No. 323 as part of the broader 2004 administrative reform that separated policy-making (vested in the Ministry of Health) from inspection + supervision (vested in Roszdravnadzor). Roszdravnadzor's headquarters is in Moscow + the agency operates through 78 Territorial Departments across the Russian Federation + employs approximately 1,500 staff at federal + territorial level. Roszdravnadzor reports directly to the Government of the Russian Federation (not to the Ministry of Health, although it is coordinated with Minzdrav).

Roszdravnadzor's structure includes:

• Central Apparatus (Moscow) — Departments of: Medicines Circulation Control + Medical Device Circulation Control + Medical Service Quality Control + Pharmaceutical Activity Licensing + Medical Activity Licensing + Legal Affairs + International Cooperation + State Service.
• Territorial Departments — 78 regional offices across the Russian Federation conducting GMP inspections, pharmacy inspections, healthcare-facility inspections + responding to citizen complaints.
• Inspection Bureau — separate FGBU institution under Roszdravnadzor conducting GMP inspections + medical-device technical inspections both domestically + abroad.
• Information Methodological Centre for Expertise, Accounting + Analysis of Medical Products Circulation (FGBU IMTsEAAOMP) — separate FGBU under Roszdravnadzor conducting laboratory + quality control + pharmacovigilance data analysis.
• All-Russian Scientific Centre for Safety of Biologically Active Substances (FGBU VNTs BAV) — separate FGBU under Roszdravnadzor conducting quality control of biologically active substances.

Roszdravnadzor's role is distinct from + complementary to Minzdrav (Ministry of Health, which owns the state registration of medicines + medical devices + sets healthcare policy + standards), SCEEMP / FGBU NTsESMP (the FGBU expert centre that conducts scientific expertise of medicines on Minzdrav's behalf, substantively the Russian equivalent of EMA + PMDA), FMBA (Federal Medical-Biological Agency, the parallel regulator for closed administrative territorial entities + occupational health), Rospotrebnadzor (Federal Service for Surveillance on Consumer Rights Protection + Human Welfare, the federal consumer-protection + sanitary-epidemiological agency that owns food + cosmetics + some IVDs) + the Eurasian Economic Commission (EEC) as the supranational regulator within the EAEU framework.

Legal foundations are Federal Law No. 61-FZ On Circulation of Medicines (12 April 2010, the Russian Medicines Law / FZ-61), Federal Law No. 323-FZ On the Fundamentals of Public Health Protection in the Russian Federation (21 November 2011), Government Decree No. 1416 of 27 December 2012 (Medical Device Registration Rules), Government Decree No. 1085 of 22 December 2011 (Medical Device Circulation Rules), Order 916 of the Ministry of Industry and Trade dated 14 June 2013 (Russian GMP Rules, substantively aligned with EU GMP + PIC/S GMP), EAEU Council Decision No. 78 of 3 November 2016 (EAEU Medicines Registration Rules), EAEU Council Decision No. 46 of 12 February 2016 (EAEU Medical Devices Registration Rules) + a substantial body of Roszdravnadzor + Minzdrav + Ministry of Industry and Trade orders implementing the federal framework.

Russia is a Permanent Member of WHO (founding member 1948); a Founding Member of the Eurasian Economic Union (EAEU) with Armenia + Belarus + Kazakhstan + Kyrgyzstan; an ICH Observer; not a PIC/S Member but maintains active PIC/S Observer engagement; an active IMDRF Observer; + leads the CIS Pharmaceutical Inspection Cooperation framework.

Understanding the Minzdrav-Roszdravnadzor split is essential to working in Russia. The two are legally distinct but operationally complementary: Minzdrav owns the State Registration decision + healthcare policy; Roszdravnadzor owns inspection, post-market surveillance + enforcement. The split mirrors (but is structurally different from) the FDA-internal organisation or the EMA-EU Commission relationship.

• Minzdrav (Ministry of Health) — owns the State Registration of Medicines (Регистрационное удостоверение лекарственного препарата) + State Registration of Medical Devices (Регистрационное удостоверение на медицинское изделие); sets pricing for Essential Medicines List (Жизненно необходимые и важнейшие лекарственные препараты / ЖНВЛП); issues Ministry of Health Orders implementing Federal Law 61-FZ + 323-FZ.
• SCEEMP / FGBU NTsESMP (Scientific Centre for Expert Evaluation of Medicinal Products) — Minzdrav-affiliated FGBU expert centre conducting scientific expertise of medicines registration dossiers on Minzdrav's behalf; substantively the Russian equivalent of EMA + PMDA scientific review functions.
• Roszdravnadzor — federal supervisory authority conducting GMP inspections, medical-device technical inspection, pharmacy + wholesale licensing, healthcare-facility inspection, pharmacovigilance + materiovigilance + Chestny ZNAK falsified-medicines enforcement.
• Roszdravnadzor's GMP inspection findings feed into Minzdrav's state-registration decisions (registration can be denied or revoked based on Roszdravnadzor inspection findings) + into the Russian GMP Certificate (Заключение о соответствии производителя лекарственных средств требованиям правил надлежащей производственной практики) issued by the Ministry of Industry and Trade (Minpromtorg) following Roszdravnadzor Inspection Bureau inspection.
• Medical device registration dossier review is conducted by FGBU 'Centre for the Examination + Testing of Medical Products' (CMICE / ВНИИИМТ) on Minzdrav's behalf; Roszdravnadzor then issues the Registration Certificate based on Minzdrav decision + conducts post-market surveillance.
• Pharmacovigilance is operated by Roszdravnadzor through the AIS Roszdravnadzor pharmacovigilance reporting system; ICSR + PSUR / PBRER submissions go to Roszdravnadzor (not Minzdrav).
• Falsified-medicines enforcement is operated by Roszdravnadzor through Chestny ZNAK (Честный ЗНАК) — the national track-and-trace system operated by the Centre for Research in Perspective Technologies (CRPT), mandatory for medicines since 1 July 2020.
• Eurasian Economic Union procedures — Russian companies + foreign applicants can choose between national-Russian registration (via Minzdrav) + EAEU registration (via EEC + Russia as Reference Member State); EAEU registration provides access to the unified EAEU market across Armenia + Belarus + Kazakhstan + Kyrgyzstan + Russia.
• Pre-2010 — registration was conducted by various Minzdrav-internal bodies + predecessor agencies; the modern Federal Law 61-FZ (April 2010) introduced the unified registration framework.
• Post-2014 — the EAEU framework introduced parallel supranational procedures; transitional provisions allow continued national-Russian registration alongside EAEU registration with full EAEU mutual recognition expected to be achieved after the harmonisation period.

Federal Law No. 61-FZ of 12 April 2010 (On Circulation of Medicines in the Russian Federation) is Russia's foundational medicines law. It has been substantially amended since 2010 to align with EAEU framework + to introduce serialisation. Key structural elements include:

• State Registration of Medicines (Государственная регистрация лекарственных препаратов) — mandatory pre-market registration of all medicines (chemical + biological + biosimilar + orphan + radiopharmaceutical) issued by Minzdrav based on SCEEMP expertise + Roszdravnadzor GMP inspection findings.
• Registration Certificate (Регистрационное удостоверение лекарственного препарата / RU LP) — the formal state-registration certificate issued by Minzdrav valid for 5 years initially + indefinitely after first renewal.
• Common Technical Document (CTD) — Russian regulatory dossier substantively aligned with ICH CTD with Russian-specific Module 1 + Russian-language Russian-Federation-specific labelling + patient information leaflet.
• Russian GMP Rules (Order 916 of Ministry of Industry and Trade, 14 June 2013) — substantively aligned with EU GMP + PIC/S GMP; mandatory for Russian manufacturers + foreign manufacturers exporting medicines to Russia; GMP Certificate issued by Minpromtorg following Roszdravnadzor Inspection Bureau inspection.
• Russian GCP Rules (Order 200n of Minzdrav, 2016) — substantively aligned with ICH E6(R2) GCP; mandatory for clinical trials conducted in Russia.
• Russian GVP Rules — substantively aligned with EU GVP Modules; Roszdravnadzor operates the AIS Roszdravnadzor pharmacovigilance reporting system for ICSR + PSUR / PBRER submissions.
• Russian Pharmacopoeia (Государственная фармакопея Российской Федерации / GFRF) — current 14th edition; Russian-specific monographs alongside ICH harmonised general chapters; mandatory reference for Russian-registered medicines.
• Essential Medicines List (Жизненно необходимые и важнейшие лекарственные препараты / ЖНВЛП) — Minzdrav-managed list of essential medicines subject to state price regulation under Federal Law 61-FZ + Government Decree No. 865.
• Chestny ZNAK serialisation — mandatory unique-identifier serialisation + aggregation for all medicines circulating in Russia since 1 July 2020; operated by CRPT (Center for Research in Perspective Technologies) under government concession.
• Federal Law 532-FZ Amendments (2014) — strengthened pharmacovigilance + introduced biosimilar regulatory framework.
• Federal Law 425-FZ Amendments (2019) — strengthened orphan-medicine framework + introduced Federal Law 61-FZ alignment with EAEU framework.
• Federal Law 449-FZ Amendments (2021) — strengthened anti-counterfeit + Chestny ZNAK enforcement framework.

Russian medical-device regulation operates under Government Decree No. 1416 of 27 December 2012 (Medical Device Registration Rules), Government Decree No. 1085 of 22 December 2011 (Medical Device Circulation Rules), Ministry of Health Order No. 4n of 6 June 2012 (Medical Device Classification Rules, substantively aligned with EU MDD / MDR principles) + EAEU Council Decision No. 46 of 12 February 2016 (EAEU Medical Devices Registration Rules). Foreign manufacturers must appoint a Russian Authorised Representative (Уполномоченный представитель производителя).

• Risk-based Classification (Class 1 / 2a / 2b / 3 + IVD Class 1-4) — substantively aligned with EU MDR / IVDR with Russian-specific overlay; classification determined by Russian Medical Device Nomenclature (Номенклатура медицинских изделий / NMI) + classification rules.
• Russian Medical Device Registration Certificate (Регистрационное удостоверение на медицинское изделие / RU MI) — issued by Roszdravnadzor based on Minzdrav decision following CMICE technical examination + Russian clinical evaluation + Russian-language labelling.
• Russian Authorised Representative (Уполномоченный представитель производителя) — Russian-resident legal entity required for foreign manufacturers; bears post-market surveillance responsibility + serves as Roszdravnadzor interface.
• CMICE (Центр экспертизы и испытаний медицинских изделий) — FGBU under Minzdrav conducting technical examination of medical-device registration dossiers + Russian-specific testing.
• Russian GOST Standards — medical-device-specific GOST R standards (substantively aligned with ISO + IEC standards) referenced in technical-file requirements; many GOST R standards are direct translations of ISO / IEC standards.
• EAEU Medical Device Registration — parallel EAEU procedure under Decision 46 with Russia as Reference Member State + Concerned Member State input; mutual recognition across Armenia + Belarus + Kazakhstan + Kyrgyzstan + Russia.
• Post-market Surveillance — Roszdravnadzor operates AIS Roszdravnadzor materiovigilance reporting system; medical-device incident reporting timelines substantively aligned with EU MDR + IMDRF Adverse Event Reporting Codes.
• ISO 13485:2016 — recognised by Roszdravnadzor as QMS evidence framework for medical-device registration; supplemented by Russian-specific GOST R ISO 13485-2017 + Russian-specific QMS audit conducted by Roszdravnadzor Inspection Bureau for certain higher-risk devices.
• MDSAP — Russia is not currently an MDSAP Participating Regulator + does not accept MDSAP audit reports as direct QMS evidence; ISO 13485 + Russian-specific overlay required.
• Russian UDI / Marking Requirements — Russia has not implemented a fully unified UDI system equivalent to FDA UDI or EU EUDAMED UDI; Russian-specific labelling + product-identification requirements apply under Government Decree 1416 + Ministry of Health Orders.

Chestny ZNAK (Честный ЗНАК, 'Honest Sign') is Russia's national track-and-trace + serialisation system for medicines + a growing range of other consumer-goods categories. It is operated by the Centre for Research in Perspective Technologies (CRPT / Центр развития перспективных технологий) under a 2017 Russian government concession + is substantively comparable to the US DSCSA + EU FMD + Turkey ITS + Saudi GHAD systems but with broader cross-category scope.

• Established by Government Decree No. 1556 of 14 December 2018 + Federal Law No. 488-FZ of 25 December 2018; Chestny ZNAK mandatory for medicines from 1 July 2020 after a 2017-2019 voluntary pilot phase + 2019-2020 mandatory phase-in.
• Unique-identifier serialisation — every primary pack of medicines circulating in Russia must bear a Chestny ZNAK 2D Data Matrix barcode containing: 14-digit GTIN + 13-character serial number (random) + verification key (cryptographic, 4 characters) + expiry date + batch number; format substantively aligned with GS1 + EU FMD serialisation.
• Aggregation + parent-child hierarchy — primary + secondary + tertiary packaging hierarchy maintained throughout supply chain with EPCIS-aligned event reporting at each transaction.
• End-to-end supply chain visibility — every transaction (manufacture, importation, distribution, dispensing, return, destruction) reported to Chestny ZNAK in near-real-time; Roszdravnadzor + Minzdrav + Federal Tax Service all have visibility into supply-chain data.
• Pharmacy verification at dispensing — pharmacies must verify Chestny ZNAK status at point of dispensing; suspect or counterfeit medicines blocked at pharmacy POS.
• Foreign manufacturer requirements — non-Russian manufacturers exporting medicines to Russia must integrate with Chestny ZNAK for serialisation + aggregation + cross-border movement reporting; integration typically managed through CMO + 3PL partners with Chestny ZNAK integration capability.
• Cross-category expansion — Chestny ZNAK has been progressively extended beyond medicines to: tobacco (2019), footwear (2020), tyres (2020), perfumes (2020), photo equipment (2020), dairy products (2021-2022), beer + low-alcohol beverages (2023-2024), bottled water (2021-2024) + other categories. Medicines remains the largest + most regulatory-intensive Chestny ZNAK category.
• Enforcement — Roszdravnadzor + Federal Tax Service enforce Chestny ZNAK requirements; non-compliant medicines face administrative fines, market withdrawal + criminal prosecution.

• EAEU established 1 January 2015 by the Treaty on the Eurasian Economic Union (Astana, 29 May 2014); Member States: Armenia + Belarus + Kazakhstan + Kyrgyzstan + Russia; Observer States: Cuba + Moldova + Uzbekistan.
• EAEU pharmaceutical + medical-device framework adopted 2016 by Council of EEC Decisions 78 (Medicines) + 46 (Medical Devices); transitional period for harmonisation with national regimes through to 2025+.
• Eurasian Economic Commission (EEC / Евразийская экономическая комиссия) — supranational regulator headquartered in Moscow; operates Department of Technical Regulation + Accreditation + Department of Sanitary, Phytosanitary and Veterinary Measures.
• Reference Member State (Уполномоченное государство-член) — applicant selects one EAEU Member State as Reference Member State; Russia is the most frequently chosen Reference Member State given market size + Russian-language dossier alignment.
• Concerned Member State (Заинтересованное государство-член) — other EAEU Member States providing input + recognising Reference Member State assessment under EAEU MRP-equivalent framework.
• EAEU GMP — substantively aligned with EU GMP + PIC/S GMP + Russian Order 916; EAEU GMP Certificate issued by Reference Member State competent authority.
• EAEU CTD — common technical document substantively aligned with ICH CTD with EAEU-specific Module 1 + multi-language (Russian + EAEU Member State languages) labelling.
• EAEU Pharmacopoeia — common pharmacopoeia under development; transitional reliance on national pharmacopoeias (Russian + Belarusian + Kazakh) + ICH harmonised general chapters.
• EAEU Pharmacovigilance — common pharmacovigilance framework with national competent-authority responsibility (Roszdravnadzor for Russia, RUE Centre for Examinations and Testing in Health Service for Belarus, etc.).
• EAEU Medical Devices — common nomenclature + classification + registration procedures; reliance on Reference Member State technical examination + national-language labelling.

• WHO Permanent Member — Russia is a founding WHO Member (1948); active participant in WHO programmes; SCEEMP + Roszdravnadzor not currently WHO-Listed Authority under the WHO PQ + WLA framework.
• EAEU Founding Member — Russia is the largest EAEU Member State + leads EAEU pharmaceutical + medical-device harmonisation; EEC Department of Technical Regulation headquartered in Moscow.
• ICH Observer — Russia is an ICH Observer; Minzdrav + SCEEMP participate in ICH Working Groups; ICH guidelines extensively referenced in Russian + EAEU regulatory practice though not formally adopted via ICH Step 5 framework.
• PIC/S Observer — Russia (Roszdravnadzor + Minpromtorg) is a PIC/S Observer + has applied for PIC/S Membership; Russian Order 916 GMP + Russian inspectorate practices substantively aligned with PIC/S GMP Guide + Annexes.
• IMDRF Observer — Roszdravnadzor + Minzdrav are IMDRF Observers; active engagement on IMDRF Working Groups including UDI + QMS + SaMD; EAEU medical-device framework draws on IMDRF + GHTF principles.
• CIS Pharmaceutical Inspection Cooperation — Russia leads the Commonwealth of Independent States (CIS) pharmaceutical inspection cooperation framework alongside Belarus + Kazakhstan + Armenia + Kyrgyzstan + Uzbekistan + Tajikistan + Azerbaijan + Moldova.
• ICMRA participation — Roszdravnadzor + Minzdrav engagement in International Coalition of Medicines Regulatory Authorities (ICMRA) on pandemic preparedness + supply-chain transparency + reliance.
• Bilateral MoUs — Roszdravnadzor + Minzdrav hold MoUs with regulators across BRICS + EAEU + CIS + Latin America + Asia including ANVISA + NMPA + MFDS + COFEPRIS + ARCSA + INVIMA + Cuban CECMED + Vietnamese DAV + Iranian FDA + Saudi SFDA + others.
• BRICS pharmaceutical cooperation — Russia leads BRICS regulatory cooperation alongside Brazilian ANVISA + Indian CDSCO + Chinese NMPA + South African SAHPRA on regulatory harmonisation + reliance.
• Sanctions environment — post-2022 international sanctions have substantially complicated Russian engagement with FDA + EMA + MHRA + Health Canada + TGA + other Western regulators; SCEEMP + Roszdravnadzor continue technical cooperation with non-Western regulators + EAEU + BRICS + CIS partners.

• Russian Authorised Representative not properly designated — application rejected at Minzdrav or Roszdravnadzor intake or post-approval compliance failure.
• Russian-language dossier deficiencies — Russian-language Module 1 + Russian-language labelling + Russian-language patient information leaflet must be accurate + culturally appropriate.
• Russian Pharmacopoeia 14th edition non-compliance — Russian-specific monograph requirements differ from USP + EP + JP in places; cross-pharmacopoeia testing required for some products.
• Order 916 GMP gaps — applicants assuming EU GMP or PIC/S GMP compliance is sufficient without addressing Russian-specific Order 916 + Russian-specific Ministry of Industry and Trade clarifications.
• Chestny ZNAK serialisation gaps — foreign manufacturers underestimating Chestny ZNAK integration complexity + Russian-specific 2D Data Matrix + verification-key + EPCIS-aligned reporting requirements.
• EAEU vs national-Russian registration strategy not planned — applicants defaulting to national-Russian registration without considering EAEU registration benefits for cross-border distribution.
• Reference Member State strategy not optimised — applicants defaulting to Russia as EAEU Reference Member State without considering Belarus or Kazakhstan alternatives for some product categories.
• Russian clinical-data requirements misjudged — many new drugs require Russian clinical-trial data; foreign-only data rarely sufficient particularly for biologics + complex generics.
• Pharmacovigilance reporting gaps — AIS Roszdravnadzor ICSR + PSUR / PBRER submission requirements substantively similar to EU GVP but with Russian-language + Russian-specific format requirements.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to EU but with Russian-specific timelines + fee structure.
• Re-registration timing missed — first re-registration must be filed within prescribed window before 5-year expiry; missed deadline triggers de-registration + market withdrawal.
• Russian + EAEU MDR-equivalent gaps — medical-device manufacturers underestimating Russian + EAEU technical-file + Russian-language IFU + Russian Authorised Representative requirements.
• ISO 13485 + Russian QMS gaps — ISO 13485:2016 recognised but Russian-specific GOST R ISO 13485-2017 overlay required + Russian QMS inspection required for higher-risk devices.
• Sanctions + supply-chain disruption — post-2022 sanctions have complicated supply-chain continuity, payment + Russian-Authorised-Representative arrangements; sponsors must validate ongoing supply-chain viability.
• Federal Importation Licence not obtained — Roszdravnadzor importation licence required in addition to Minzdrav registration; missed step prevents market entry.

V5 Ultimate provides the operational infrastructure Russian + EAEU manufacturers + foreign-supplier sites need for Federal Law 61-FZ + Government Decree 1416 + Order 916 + EAEU Decision 78 + Decision 46 + Chestny ZNAK compliance + Roszdravnadzor + Minzdrav readiness.

• Russian Order 916 GMP control framework — EU GMP + PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Russian-specific Order 916 + Minpromtorg-specific elements + Russian-language quality records.
• EAEU GMP framework — EAEU Council Decision GMP requirements alongside national-Russian Order 916 + Belarusian + Kazakh GMP equivalents.
• Minzdrav state-registration packaging — Russian CTD-aligned dossier structure with Russian Module 1 specifics + SCEEMP scientific-expertise packaging + Russian-language Module 1 + 2.7 + 3.2.P + 3.2.S.
• EAEU registration packaging — EAEU Reference Member State + Concerned Member State workflow with EAEU CTD + multi-language labelling + national-language patient information leaflet.
• Russian Authorised Representative workflow — foreign-manufacturer Russian Authorised Representative designation + role-management + Russian-specific post-market surveillance + Roszdravnadzor interface.
• Chestny ZNAK serialisation — full Chestny ZNAK 2D Data Matrix + 14-digit GTIN + 13-character serial + 4-character verification key + expiry + batch generation + aggregation + EPCIS-aligned reporting + integration with CMO + 3PL + Russian Authorised Representative.
• Russian clinical-trial workflow — Russian GCP-aligned site management + Russian Ethics Committee approval + Minzdrav CTA submission + AIS Roszdravnadzor SUSAR reporting + Russian Pharmacopoeia + GFRF compliance.
• AIS Roszdravnadzor pharmacovigilance — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Russian-language ICSR + Russian-specific format + AIS Roszdravnadzor submission.
• Medical-device registration + materiovigilance workflow — Government Decree 1416 + EAEU Decision 46 dossier packaging + Class 1 / 2a / 2b / 3 + IVD Class 1-4 classification + ISO 13485 + Russian QMS audit + Russian Authorised Representative + AIS Roszdravnadzor materiovigilance reporting.
• Russian + EAEU Variations workflow — Type IA / IB / II classification + Minzdrav / EAEU procedure + Russian-language packaging.
• Re-registration workflow — first re-registration 5-year window tracking + Russian + EAEU procedure packaging.
• BRICS + EAEU + CIS bridging — for companies operating across BRICS + EAEU + CIS, V5 surfaces Russian + EAEU + Belarusian + Kazakh + Armenian + Kyrgyz harmonised dossier-element reuse alongside national-specific extensions.